Predict your next investment

HEALTHCARE | Drug Development
frequencytx.com

See what CB Insights has to offer

Founded Year

2015

Stage

IPO | IPO

Total Raised

$216M

Date of IPO

10/3/2019

Market Cap

0.30B

Stock Price

6.87

About Frequency Therapeutics

Frequency Therapeutics (NASDAQ: FREQ) is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases.

Frequency Therapeutics Headquarter Location

19 Presidential Way

Woburn, Massachusetts, 01801,

United States

866-389-1970

Latest Frequency Therapeutics News

Decibel Therapeutics announces study on noise-related inner ear damage

Sep 30, 2021

Drug Discovery and Development September 30, 2021 Decibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. The Boston-based biotech company has announced that a recent study published in  Cell Reports  supports that hypothesis. “We were thrilled to leverage our data and expertise in inner ear biology to help fuel this analysis, which may help enable identification of therapeutics that counter the observed trends in gene expression that occur following noise exposure,” said Joe Burns, vice president, discovery at Decibel Therapeutics, in a statement. The company partnered with the University of Maryland School of Medicine and the Karolinska Institute on the research. Decibel Therapeutics had its IPO on February 12. Its shares have since fallen from $18.03 apiece to $7.71 today. Other hearing-loss-focused pharmaceutical forms have also see wide declines. For instance, Otonomy (NSDQ:OTIC) has had its shares fall from $39.36 on March 13, 2015 to $1.92 today. Similarly, Lexington, Massachusetts–based Frequency Therapeutics has also seen its stock plunge from $55.01 on February 19 to $7.06 today. On March 23, Frequency Therapeutics (NSDQ:FREQ) announced that interim results indicated that its lead pipeline candidate FX-322 was ineffective at improving mild to moderately severe sensorineural hearing loss in a Phase 2a study compared to placebo. Earlier that month, the company said the drug seemed to lead to hearing improvements in adults with age-related hearing loss . Frequency Therapeutics recently announced that several subjects receiving FX-322 in a small open-label study showed statistically significant hearing improvement eight to 12 months after initial dosing.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Frequency Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Frequency Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Frequency Therapeutics Patents

Frequency Therapeutics has filed 19 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Cell biology
  • Stem cells
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2017

7/20/2021

Transcription factors, Stem cells, Auditory system, Pyridines, Cell biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/21/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/20/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Stem cells, Auditory system, Pyridines, Cell biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Frequency Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Frequency Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.